香港股市 已收市

AKBA Jun 2024 1.500 put

OPR - OPR 延遲價格。貨幣為 USD。
加入追蹤清單
0.6000+0.2100 (+53.85%)
市場開市。 截至 10:34AM EDT。
全螢幕
前收市價0.3900
開市0.6000
買盤0.2500
賣出價1.2500
拍板1.50
到期日2024-06-21
今日波幅0.6000 - 0.6000
合同範圍
成交量6
未平倉合約181
  • Insider Monkey

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript

    Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q1 2024 Earnings Call Transcript May 9, 2024 Akebia Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.08775, expectations were $-0.09. AKBA isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Hello, and welcome to the Akebia’s […]

  • Zacks

    Akebia Therapeutics (AKBA) Reports Q1 Loss, Misses Revenue Estimates

    Akebia Therapeutics (AKBA) delivered earnings and revenue surprises of 0% and 20.72%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

  • Benzinga

    FDA Approves For Akebia Therapeutics' Vafseo For Kidney Disease Associated Anemia

    Wednesday, the FDA approved Akebia Therapeutics Inc (NASDAQ:AKBA) Vafseo (vadadustat) tablets for anemia due to chronic kidney disease (CKD) in adults who have been receiving dialysis for at least three months. Vafseo is a once-daily oral hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor that activates the physiologic response to hypoxia to stimulate endogenous production of erythropoietin to manage anemia. Vafseo is now approved in 37 countries. The approval of Vafseo is based on e